Patents by Inventor Stuart C. Apfel

Stuart C. Apfel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF BUTYLPHTHALIDE AND DERIVATIVE THEREOF
    Publication number: 20230144023
    Abstract: The present application provides application of butylphthalide or optical isomer, prodrug, deuterium, metabolite, and ring-opening product or ring-opening product salt thereof in the preparation of a drug for preventing, alleviating, or treating peripheral neuropathy, especially chemotherapy-induced peripheral neuropathy, and a use method of butylphthalide and a derivative thereof in preventing or treating peripheral neuropathy, especially chemotherapy-induced peripheral neuropathy. In vivo and in vitro studies show that the drug of the present invention can effectively prevent, alleviate, or treat peripheral neuropathy caused by chemotherapy drugs without affecting the tumor-inhibiting efficacy and pharmacokinetic properties of the chemotherapy drugs.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 11, 2023
    Inventors: Xibao LIU, Yanling LI, Jieru LIU, Stuart C. APFEL, Yuxiu MA, Xiaojuan WU, Yuqing WANG, Hanyu YANG
  • Use of growth factors to treat drug-inducted neuropathy
    Patent number: 6011004
    Abstract: This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .alpha. (TFG-.alpha.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: January 4, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: John A. Kessler, Stuart C. Apfel
  • Prevention and treatment of peripheral neuropathy
    Patent number: 5648335
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: July 15, 1997
    Assignees: Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva Univ.
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Prevention and treatment of peripheral neuropathy
    Patent number: 5633228
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: May 27, 1997
    Assignees: Cephalon, Inc.,, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Use of NGF growth factors to treat drug-induced neuropathy
    Patent number: 5604202
    Abstract: This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .varies. (TFG-.varies.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: February 18, 1997
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: John A. Kessler, Stuart C. Apfel
  • Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
    Patent number: 5585348
    Abstract: This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: December 17, 1996
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Stanley M. Crain, Ke-fei Shen, John A. Kessler, Stuart C. Apfel
  • Prevention and treatment of peripheral neuropathy
    Patent number: 5569648
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: October 29, 1996
    Assignees: Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Prevention and treatment of peripheral neuropathy
    Patent number: 5420112
    Abstract: The invention features a method of preventing or treating a peripheral neuropathy that results from a systemic disease (e.g., post-polio syndrome) or a toxic agent (e.g., a chemotherapeutic agent), and that is not caused by an abnormal insulin level in a mammal. The method involves administering a neuropathy-reducing amount of insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to the mammal.
    Type: Grant
    Filed: April 16, 1993
    Date of Patent: May 30, 1995
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler